Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
Recruiting now · Phase 1
Conditions studied: Immune Thrombocytopenia
In brief
The goal of this clinical trial is to demonstrate GL-2045 safety and efficacy proof of concept by demonstrating intravenous immunoglobulin (IVig)-like platelet responses in adult patients with Immune Thrombocytopenia (ITP).
Key facts
- Study ID
- NCT07605845
- Run by
- Gliknik Inc.
- People needed
- 42
- Starts
- 2026-04-14
- Expected to finish
- 2027-12-06
- Last updated by the study team
- 2026-05-26
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fortrea Clinical Research Unit Ltd — Leeds, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.